A Critical Pathway for Implantable Cardioverter-Defibrillators in Patients With Ischemic Cardiomyopathy (CAPTURE)
The purpose of this study is to develop and implement a critical pathway to identify patients with ischemic cardiomyopathy who are candidates for an implantable cardioverter-defibrillator (ICD). This study will also determine whether the use of the critical pathway for ICDs is associated with a change in the ICD referral and implantation rate.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Health Services Research
|Official Title:||A Critical Pathway for Implantable Cardioverter-Defibrillators in Patients With Ischemic Cardiomyopathy|
- Rate of Referral for ICD Assessment [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- Rate of ICD Implantation [ Time Frame: 1 year ] [ Designated as safety issue: No ]
|Study Start Date:||April 2012|
|Estimated Study Completion Date:||May 2012|
|Estimated Primary Completion Date:||May 2012 (Final data collection date for primary outcome measure)|
|Experimental: Critical Pathway||
Other: Use of the ICD Critical Pathway
The critical pathway is a series of predetermined processes designed to assess a patient's eligibility for an ICD. The critical pathway will incorporate current evidence-based practice guidelines.
Other Name: ICD Critical Pathway
|No Intervention: Standard Practice|
Despite improvements in both medical management and revascularization strategies, sudden death is still a significant complication in patients with ischemic cardiomyopathy. There is strong evidence to support the role of ICDs for the primary prevention of sudden death in this population. However, in Canada and the United States, ICDs are underutilized.
Critical pathways are algorithms that improve health care delivery and clinical outcomes while reducing practice variability. The use of a critical pathway to assess a patient's eligibility for an ICD may increase the appropriate use of this evidence-based technology.
|Contact: S Cowan, MD, MSc||(604) 682 email@example.com|
|Canada, British Columbia|
|St. Paul's Hospital||Not yet recruiting|
|Vancouver, British Columbia, Canada, V6Z 1Y6|
|Contact: S Cowan, MD, MSc (604) 682 2344 firstname.lastname@example.org|
|Sub-Investigator: S Cowan, MD, MSc|
|Sub-Investigator: A Ignaszewski, MD|
|Principal Investigator: C Kerr, MD|
|Sub-Investigator: S Tung, MD|
|Study Director:||S Cowan, MD, MSc||St. Paul's Hospital, Vancouver, British Columbia|
|Study Director:||A Ignaszewski, MD||St. Paul's Hospital, Vancouver, British Columbia|
|Principal Investigator:||C Kerr, MD||St. Paul's Hospital, Vancouver, British Columbia|
|Study Director:||S Tung, MD||St. Paul's Hospital, Vancouver, British Columbia|